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Letters to the Editor
that we appropriately adjusted for several of the potential 
confounding variables highlighted by Dr Aitchison in our 
statistical models, including rape, household income, and 
marital status.
Please see our response to another “Letter to the Editor”3 
for further details.
Natalie P Mota, MA
Margaret Burnett, MD, FRCPC
Jitender Sareen, MD, FRCPC
Winnipeg, Manitoba
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New Psychotherapies for Mood and Anxiety 
Disorders: Necessary Innovation or Waste of 
Resources?
Dear Editor:
With much interest we read the systematic review from 
Stirman et al1 about new psychotherapies for mood and 
anxiety disorders. Although the study has been well 
conducted, we think the authors have not suffi ciently 
answered the question of whether we actually need new 
psychotherapies.
On the one hand, there is a clear need for better treatments, 
as mood and anxiety disorders constitute a considerable 
burden for patients and society. Further, modelling studies 
have shown that current treatments can reduce only 
one-third of the disease burden of depression and less than 
one-half of anxiety disorders, even in optimal conditions.2
However, there are already dozens of different types of 
psychotherapy for mood and anxiety disorders, and there 
is very little evidence that the effects of treatments differ 
signifi cantly from each other. In depression, we found that 
interpersonal psychotherapy is somewhat more effective 
than other therapies,3 but differences were very small 
(Cohen’s d < 0.21) and the clinical relevance is not clear. 
In the fi eld of anxiety disorders, there is evidence that 
relaxation is less effective than cognitive-behavioural 
therapy, but there is very little evidence for signifi cant 
differences between other therapies.
We think that new therapies are only needed if the 
additional effect compared with existing therapies is 
at least d = 0.20. Larger effect sizes are not reasonable 
to expect as 0.20 is the largest difference between 
therapies found until now. Further, this effect needs 
to be empirically demonstrated in high-quality trials. 
However, to show such an effect of 0.20 we would need 
huge numbers. A simple power calculation shows that this 
would require a trial of about 1000 participants (STATA 
[Statacorp, College Station, TX] sampsi command). As a 
comparison, the large National Institute of Mental Health 
Treatment of Depression Collaborative Trial examining 
the effects of treatments of depression included only 
250 patients.
We want to suggest, therefore, that the fi eld stops with 
developing new psychotherapies for mood and anxiety 
disorders unless the developers can convince fi nancers 
of research to conduct a well-powered comparative study 
that shows that this therapy is indeed more effective than 
existing therapies. In the meantime, the fi eld should focus 
on the real problems that limit the contribution of therapies 
to the reduction of disease burden, including the large 
number of patients who do not respond to any treatment, 
the patients who still have considerable residual symptoms 
after successful treatments, and patients who relapse.
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Pim Cuijpers, PhD
Annemieke van Straten, PhD
Amsterdam, The Netherlands
 Reply
Re: New Psychotherapies for Mood and 
Anxiety Disorders: Necessary Innovation or 
Waste of Resources?
Dear Editor:
We certainly agree with Dr Cuijpers and Dr van Straten 
that to date there have not been many examples of clear 
successes in developing new psychotherapies that are 
measurably superior to existing psychotherapies.
But there are good reasons why the fi eld should not 
stop attempting to develop new psychotherapies. As 
Dr Cuijpers and Dr van Straten make clear, we need 
ways to address lack of response, residual symptoms, and 
relapse rates associated with existing treatments. Other 
than sequencing or combined existing treatments, or 
attempting to match treatments to patient characteristics, 
the development of new psychotherapies that target 
nonresponders, residual symptoms, and (or) relapse is the 
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only other way to address these signifi cant limitations of 
existing treatments. In fact, some of the innovations in 
psychotherapy development over the past 20 years have 
been along these lines (for example, relapse prevention 
strategies or well-being therapy for residual symptoms).
Dr Cuijpers and Dr van Straten discuss the need for 
large sample sizes to adequately test for incremental 
improvements above that found with existing treatments. 
We agree that funding agencies should recognize that, to 
make progress in testing new treatments against existing 
treatments, larger sample sizes than used in the past are 
needed. However, the 0.20 effect size recommended 
by Dr Cuijpers and Dr van Straten is arbitrary. Sample 
size estimation changes considerably depending on the 
specifi ed effect size. For example, if one is satisfi ed with 
having adequate power (0.80) to detect a Cohen’s d effect 
size of 0.28 (which is still rather small), only 200 patients 
per group (α = 0.05; 2-tailed) are needed, a number that is 
more reasonable, though still larger than what has typically 
been used in the past. Further, including a larger number 
of assessment points can increase statistical power, further 
reducing the needed sample size.
One cannot stop innovation—we suspect imaginative 
clinicians and researchers will continue to generate 
new ideas. In addition, because we do not know in 
advance whether a new treatment will achieve the 0.20 
effect size (or any other effect size) compared with an 
existing treatment, it is not possible to stop the treatment 
development process at an early stage. However, 
Dr Cuijpers and Dr van Straten’s reminder that often new 
psychotherapies are no better than existing ones suggests 
that if an investigator wants to develop a new treatment, 
it would be more effi cient to cut to the chase and test the 
new treatment against an established one. This would be 
preferable to conducting a series of studies comparing the 
new treatment with relatively weak control conditions so 
that effi cacy is fi rst demonstrated, only to later fi nd out 
that the new treatment is no better than existing ones. 
Tests of comparative effi cacy have the further advantage 
of allowing earlier investigation and characterization of 
different patterns of response to active treatments among 
patients with particular characteristics. Such research 
will ultimately allow us to optimize the fi t of patients to 
treatments and to reduce the likelihood of nonresponse.
Paul Crits-Christoph, PhD
Shannon Wiltsey Stirman, PhD
Philadelphia, Pennsylvania
